Neurim Pharmaceuticals

Company Overview

Snapshot

Founded in June 1991 by Nava Zisapel, Neurim Pharmaceuticals operates with 11–50 employees. The company has secured funding across one disclosed round from one investor, Prof. Nava & Yehuda Zisapel. A significant milestone for the company was Health Canada's marketing authorization for Slenyto® in September 2025.

Business overview

Neurim Pharmaceuticals is a drug discovery and development company specializing in creating pharmaceuticals for brain restoration and support. The company focuses on addressing insomnia, central nervous system-related problems, and neurodegenerative diseases. Its product portfolio includes Circadin, a timed-release melatonin for insomnia, and Slenyto, a pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder and/or Smith-Magenis syndrome. Neurim Pharmaceuticals serves markets in Europe, the Asia-Pacific region, and the Middle East within the Health Tech & Life Sciences sector.

Strategic signal

In September 2025, Health Canada granted marketing authorization for Slenyto®, Neurim Pharmaceuticals' extended-release melatonin formulation, as a prescription drug for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome. This approval is a significant validation of the company's pediatric drug development efforts, expanding its market reach and reinforcing its position in addressing neurodevelopmental sleep disorders.

Company Intelligence Q&A

What was a key regulatory approval for Neurim Pharmaceuticals in 2025?

In September 2025, Health Canada granted marketing authorization for Slenyto®, Neurim Pharmaceuticals' extended-release melatonin formulation, as a prescription drug for insomnia in children with autism spectrum disorder and Smith-Magenis syndrome.

Which product did Neurim Pharmaceuticals grant marketing rights for in Spain?

In March 2017, Neurim Pharmaceuticals granted Exeltis marketing rights for Paediatric Prolonged-Release Melatonin (PedPRM) in Spain.

What was the outcome of Neurim Pharmaceuticals' Alzheimer's disease trial in 2014?

In June 2014, Neurim Pharmaceuticals reported success in an Alzheimer's disease trial.

What positive opinion did Neurim Pharmaceuticals receive for Slenyto in 2018?

In July 2018, Neurim Pharmaceuticals received a positive CHMP opinion for Slenyto (Pediatric Prolonged-Release Melatonin) for the treatment of insomnia in children with Autism Spectrum Disorder (ASD).

Who founded Neurim Pharmaceuticals?

Neurim Pharmaceuticals was co-founded by Nava Zisapel.